Vikram Aroma (544371)
TurnaroundScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹66.17 |
| Market Cap | ₹20.75 Cr |
| P/E Ratio | 0 |
| ROCE | -4.83% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | 63.64% |
| Debt/Equity | — |
| Sales Growth | -49.09% |
| Sector | Chemicals & Petrochemicals |
Strengths
- Latest quarter still generated ₹5 crore in sales, indicating a live operating entity.
- Reported profit growth of +63.64%, though off a low or negative base, suggests some improvement.
- Piotroski F-score of 5/9 shows a few basic financial health checks are passing.
- Small ₹21 crore market cap means a modest absolute earnings recovery could have a significant impact.
Concerns
- Revenue down 49.09% year-on-year, showing a sharp demand or business contraction.
- ROCE is negative at -4.83%, meaning existing capital is earning poor returns.
- Latest quarter net profit is -₹0 crore; there is no positive earnings to support valuation.
- Book value, debt/equity, promoter holding and 52-week range are unavailable, limiting a margin-of-safety assessment.
AI Analysis
At ₹21 crore market cap, Vikram Aroma is a micro-cap in specialty chemicals. I cannot develop conviction without a moat, and I see no evidence of one from these numbers. Sales collapsed 49.09%, latest quarter at ₹5 crore, and capital employed is earning a negative 4.83% ROCE. This means the business is currently destroying value, not compounding it. The reported profit growth of 63.64% is a base-effect illusion; the latest quarter still shows net profit of -₹0 crore, essentially at break-even or small loss. P/E of 0.00 confirms there is no meaningful earnings yield to attach to. As Graham, I first look for downside protection: book value, debt/equity, promoter holding are all unavailable, so I cannot measure asset cover or insider alignment. A Piotroski score of 5/9 is mediocre, not a distress signal but certainly not evidence of a high-quality balance sheet. Dividend yield is nil; I am not being paid to wait. Specialty chemicals can be cyclical, but a nearly 50% drop in revenue points more to a turnaround situation with execution risk than to a temporary cycle. I would need several quarters of stabilizing sales, positive operating cash flow, and visible margins before assigning any intrinsic value. At ₹66.17, the price is low, but a rupee price alone is not a margin of safety. Without data on assets and liabilities, I prefer to pass. In investing, avoiding losses matters more than catching every speculative bounce. This is a possible turnaround, but only after evidence appears.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer